Major Limitations of Cardiovascular Risk Scores

Background. Epidemiological studies conducted in extensive population cohorts have led to the creation of numerous cardiovascular risk predictor models. However, these tools have certain limitations that restrict its applicability. The aim behind the following work is to summarize today's best-...

Full description

Saved in:
Bibliographic Details
Main Authors: Ibtissam Talha (Author), Noureddine Elkhoudri (Author), Abderraouf Hilali (Author)
Format: Book
Published: Hindawi-Wiley, 2024-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_00e7a85b02da4afb9569b4f2ceb50ed3
042 |a dc 
100 1 0 |a Ibtissam Talha  |e author 
700 1 0 |a Noureddine Elkhoudri  |e author 
700 1 0 |a Abderraouf Hilali  |e author 
245 0 0 |a Major Limitations of Cardiovascular Risk Scores 
260 |b Hindawi-Wiley,   |c 2024-01-01T00:00:00Z. 
500 |a 1755-5922 
500 |a 10.1155/2024/4133365 
520 |a Background. Epidemiological studies conducted in extensive population cohorts have led to the creation of numerous cardiovascular risk predictor models. However, these tools have certain limitations that restrict its applicability. The aim behind the following work is to summarize today's best-known limitations of cardiovascular risk assessment models through presenting the critical analyses conducted in this area, with the intention of offering practitioners a comprehensive understanding of these restrictions. Critical analyses revealed that these scales exhibit numerous limitations that could impact their performance. Most of these models evaluate cardiovascular risk based on classic risk factors and other restrictions, thereby negatively affecting their sensitivity. Scientists have made significant advancements in improving cardiovascular risk models, tailoring them to accommodate a wide range of populations and devising scales for estimating cardiovascular risks that can account for all prevailing restrictions. Better understanding these limitations could improve the cardiovascular risk stratification. 
546 |a EN 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Diseases of the circulatory (Cardiovascular) system 
690 |a RC666-701 
655 7 |a article  |2 local 
786 0 |n Cardiovascular Therapeutics, Vol 2024 (2024) 
787 0 |n http://dx.doi.org/10.1155/2024/4133365 
787 0 |n https://doaj.org/toc/1755-5922 
856 4 1 |u https://doaj.org/article/00e7a85b02da4afb9569b4f2ceb50ed3  |z Connect to this object online.